
    
      It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase
      of pharmacological treatment of patients with schizophrenia. However, this classical strategy
      produces long term adverse events of drug such as TD, osteoporosis and some metabolic
      syndrome. To overcome these adverse events, new strategy for pharmacological treatment is
      needed.
    
  